A S with so many issues in biogerontology, the most satisfying understanding of why there is a coupling of cancer to aging comes from evolutionary biological considerations. Researches from the Campisi and Sharpless laboratories continue to support the notion of antagonistic pleiotropy. Early life course gene actions have been selected to attenuate somatic proliferation via cellular or replicative senescence as a tumor suppression mechanism. Late in the life course, however, when phenotypes will have escaped the force of natural selection, the seeding of tissues with senescent cells can lead to tumor promotion via a " fi eld effect " resulting from their senescence-associated secretory phenotype (SASP). The decline in late life regenerative potential (that involves stem cells and their niches) likely contributes to a variety of senescent phenotypes.
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Although childhood forms of cancer are of major clinical signifi cance, the vast majority of human neoplasms appear to be coupled to the biology of aging in that their age-specifi c incidences begin to rise steadily (and often exponentially) after the emergence of the mature adult phenotype. The same can be said for the majority of neoplasms in all mammalian species in which the relationship has been suffi ciently probed. It can be argued (as was pointed out in the special lecture by Harvey Jay Cohen) that, with the apparent exception of adenocarcinomas of the prostate and colon, an initial exponential or near-exponential age-related increase eventually tapers off during the last decades of life. Perhaps, however, this is related to the accompanying atrophy observed in many tissues during aging, with the result that the target cell types have been substantially diminished. So we are faced with this mystery of the mechanism(s) underlying this striking coupling of cancer with aging.
The American Federation for Aging Research (AFAR) Conference on Aging and Cancer did not solve these problems, but did present us with a coherent theory based upon evolutionary biological considerations. Moreover, we heard clear evidence of progress on a number of highly relevant issues such as stem cell biology, mitochondrial biology, and systems biology. There was much that could have been added, notably more information on epigenetic mutations and the numerous disruptions of gene networks that unfold during the genesis of malignant neoplasms.
Our conference commenced with a series of very diverse presentations covering a wide range of issues dealing with the interface of cancer and aging. Readers wishi ng to learn more about the current status of these innovative programs, which address important clinical as well as basic issues, should contact our speakers: Sanjay Asthan, University of His outline of the cultural and economic implications of the demographic trends in our society (lots of old people and fewer young ones to take care of them) was indeed sobering. Cancer has now overtaken heart disease as the major cause of mortality. The need for research on the pathogenetic interface with the biology of aging therefore represents a major challenge and opportunity.
Judy Campisi gave a brilliant overview of current biological research in cancer and aging and presented new data on SASP (the senescence cell -associated secretory phenotype) that was published 2 months after the conference ( 2 ). I fi nd her ideas quite compelling, and her efforts to examine these issues in vivo, with a focus on prostatic cancer, is a particularly important new direction.
Steve Austad reviewed the classical evolutionary biological theory of why we age ( 3 ) and put cancer and aging in that context. He is now a leader in the comparative biology of aging, a fi eld that promises to reveal much about differential susceptibilities to cancer as well as aging ( 4 ) . For example, Shelly Buffenstein has pioneered research on the amazingly long-lived naked mole rat (which enjoys a circa eightfold longer maximum life span than comparably sized laboratory mice). Remarkably, she has never observed a cancer in these animals. Most of her recent works have addressed the oxidative damage theory of aging. Naked mole rats appear to tolerate a remarkable degree of such damage to their macromolecules, but such damage does not appear to increase during aging ( 5 ) .
Larry Loeb, the originator of the mutator phenotype as a key to the development of malignancies, reviewed new data on the characterization of mutations ( 6 ) . He also reviewed some of my own data, the fi rst to report on the rising frequencies of somatic mutations of an epithelial cell type during aging ( 7 ). Larry's laboratory has pioneered the development of an exquisitely sensitive assay for both nuclear and mitochondrial mutations ( 8 , 9 ) . These assays have been applied to the investigations of both cancer and aging ( 10 ) .
Tom Rando bought us up to date on how stem cell functions change with aging. His work has dealt mainly with skeletal muscle stem cells, but the results are likely to have lessons for a variety of stem cells, particularly the importance of the stem cell microenviroment, or niche ( 11 ) . He presented new research highlighting the importance of the Wnt as well as the Notch pathways in stem cell behavior during aging ( 12 ) . Norm Sharpless has long been interested in DNA damage and genes that not only prevent cancer but also compromise organismal fi tness by limiting tissue regeneration and repair ( 13 ) . He reviewed his pioneering studies of how p16(INK4a) not only acts as a tumor suppressor but also diminishes regenerative pathways during aging. This too can be put into the context of the evolutionary biological concept of trade-offs in gene action.
Jack Griffi th reviewed his pioneering work on the fi ne structure of telomeres and the implications for function, both in cancer and in aging. His early work with Titia de Lange has now become a classic in biology ( 14 ) . His research has expanded to encompass such subjects as the Werner syndrome helicase -exonuclease ( 15 ) and the repair of DNA cross-links ( 16 ) . Jack pointed out that there were some laboratories developing new evidence for novel RNAs associated with telomeres. Thus, we are nowhere near the end of learning about the end of chromosomes and how they contribute to replicative senescence and oncogenesis! We turned to a master clinician, Harvey Jay Cohen, to sum up what we can learn from " fl ipping the coin " between cancer and aging. Harvey has thought about this interface during his many years of geriatric practice. He pointed out the many gaps in our understanding of basic science, clinical issues, and societal issues related to that interface ( 17 ) . For starters, we really have little understanding of the late life declines in the age-specifi c incidence of many important cancers.
Our meeting ended with a roundtable discussion led by representatives of industry. Among the problems discussed was the fact that only about one in 10 promising therapeutic compounds make it to Phase III clinical trials. G.M.M. a lso lamented the loss of " curiosity-driven research " in industry.
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